 Cantor Fitzgerald restated their overweight rating on shares of Crinetics Pharmaceuticals NASDAQ:CRNX in a research report released on Wednesday, Zacks.com reports. A number of other equities analysts have also recently commented on CRNX. TheStreet cut shares of Crinetics Pharmaceuticals from a c- rating to a d rating in a report on Friday, February 21st. HC ... 